BR0209360A - Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose - Google Patents

Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose

Info

Publication number
BR0209360A
BR0209360A BR0209360-0A BR0209360A BR0209360A BR 0209360 A BR0209360 A BR 0209360A BR 0209360 A BR0209360 A BR 0209360A BR 0209360 A BR0209360 A BR 0209360A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
inhalation
administration
osteoporosis
Prior art date
Application number
BR0209360-0A
Other languages
English (en)
Inventor
Nageswara R Palepu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0209360A publication Critical patent/BR0209360A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO DE ADMINISTRAçãO DE BISFOSFONATOS POR INALAçãO NO TRATAMENTO OU PREVENçãO DE REABSORçãO óSSEA E OSTEOPOROSE". A presente invenção refere-se ao tratamento e prevenção de doenças ósseas em seres humanos, incluindo a osteoporose em mulheres que se encontram no período pós-menopausa, Doença de Paget e hipercalcemia, mediante administração de um bisfosfonato em uma forma de inalação. A invenção também refere-se a composições farmacêuticas de inalação adequadas para o tratamento e prevenção de doenças ósseas.
BR0209360-0A 2001-05-02 2002-05-02 Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose BR0209360A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84782701A 2001-05-02 2001-05-02
PCT/EP2002/004821 WO2002089816A1 (en) 2001-05-02 2002-05-02 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis

Publications (1)

Publication Number Publication Date
BR0209360A true BR0209360A (pt) 2004-06-08

Family

ID=25301603

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209360-0A BR0209360A (pt) 2001-05-02 2002-05-02 Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose

Country Status (11)

Country Link
US (2) US6743414B2 (pt)
EP (1) EP1392325B1 (pt)
JP (1) JP2004528365A (pt)
CN (1) CN100345549C (pt)
AT (1) ATE330616T1 (pt)
BR (1) BR0209360A (pt)
CA (1) CA2444718A1 (pt)
DE (1) DE60212621T2 (pt)
ES (1) ES2268086T3 (pt)
PT (1) PT1392325E (pt)
WO (1) WO2002089816A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
EA200900095A1 (ru) * 2006-11-21 2009-08-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Лекарственные формы бифосфонатов для ингаляции и способы их применения
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102573809B (zh) 2009-07-31 2017-07-21 格兰泰股份有限公司 结晶方法和生物利用度
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN105640924B (zh) * 2016-01-18 2018-11-02 杭州旦杰医学科技有限公司 用于呼吸道给药的阿仑膦酸钠粉雾剂及其制备方法和用途
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN111053761B (zh) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 一种吸入用双膦酸类药物及其制备方法及其在慢性阻塞性肺疾病的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE182C (de) * 1877-08-02 A. LANGE & SÖHNE in Glashütte, Sachsen Sekundenwerk mit springendem Zeiger
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
ATE176476T1 (de) * 1992-12-02 1999-02-15 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
PL321835A1 (en) * 1995-02-17 1997-12-22 Merck & Co Inc Method of reducing the risk of non-vertebral bone fracture
US5686114A (en) * 1995-06-02 1997-11-11 University Of Iowa Research Foundation Uses of inorganic pyrophosphates
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
AU8493698A (en) * 1997-07-22 1999-02-16 Merck & Co., Inc. Method for inhibiting bone resorption
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
US6414006B1 (en) * 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
CN100358494C (zh) * 1998-11-12 2008-01-02 弗兰克G·皮尔基威克兹 一种吸入给药***
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods

Also Published As

Publication number Publication date
US20030064966A1 (en) 2003-04-03
CN100345549C (zh) 2007-10-31
DE60212621D1 (de) 2006-08-03
CA2444718A1 (en) 2002-11-14
PT1392325E (pt) 2006-10-31
ATE330616T1 (de) 2006-07-15
US6743414B2 (en) 2004-06-01
CN1505517A (zh) 2004-06-16
JP2004528365A (ja) 2004-09-16
ES2268086T3 (es) 2007-03-16
EP1392325A1 (en) 2004-03-03
US20040127466A1 (en) 2004-07-01
WO2002089816A1 (en) 2002-11-14
EP1392325B1 (en) 2006-06-21
DE60212621T2 (de) 2007-06-14

Similar Documents

Publication Publication Date Title
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
MY146809A (en) Treatment and prevention of osteoporosis
CO4560546A1 (es) Formulacion con granulacion en humedo de acidos bisfosfonicos
BR0209360A (pt) Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
WO2005025504A3 (en) Modulators of calcitonin and amylin activity
WO2004058235A3 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
EP0341961A3 (en) Polymalonic acids as boneaffinity agents
BR9808233A (pt) Preparação farmacêutica
IS4392A (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga
GB9821671D0 (en) Plant extracts for the treatment of increased bone resorption

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.